Presidential Symposium IDate Sat, 10.09.2022 Time 16:30 - 18:00 LBA1 - Mechanism of Action and an Actionable Inflammatory Axis for Air Pollution Induced Non-Small Cell Lung Cancer: Towards Molecular Cancer Prevention LBA2 - DeFi: A Phase 3, Randomized Controlled Trial of Nirogacestat Versus Placebo for Progressing Desmoid Tumors (DT) LBA3 - Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase 3 trial Presidential Symposium IIDate Sun, 11.09.2022 Time 16:30 - 18:05 LBA4 - Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase 3 CheckMate 914 trial LBA5 - Primary results of the phase 3 KEYNOTE-412 study: pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) LBA6 - Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801) Presidential Symposium IIIDate Mon, 12.09.2022 Time 16:30 - 18:15 LBA8 - Phase 3 study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313) LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: first results of the RADICALS-HD trial (ISRCTN40814031) LBA11 - IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Proffered Paper session: Breast cancer, metastaticDate Fri, 09.09.2022 Time 16:00 - 17:30 LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC) LBA16 - Dalpiciclib plus letrozole or anastrozole as 1st-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): a phase 3 trial LBA17 - Primary endpoint results of SYNERGY, a randomized phase 2 trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC). Proffered Paper session: Gynaecological cancersDate Fri, 09.09.2022 Time 14:00 - 15:30 LBA29 - Final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) LBA30 - Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC) LBA31 - Randomized phase 3 trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial Proffered Paper session: Investigational immunotherapyDate Fri, 09.09.2022 Time 16:00 - 17:15 LBA37 - A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung) —— 卧槽！ LBA38 - BNT211-01: A Phase 1 trial to evaluate safety and efficacy of CLDN6 CAR T cells and CLDN6-encoding mRNA vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumours Proffered Paper session 1: GI, upper digestiveDate Sat, 10.09.2022 Time 08:30 - 09:50 三光日月星，四诗风雅颂 这三位凑到一起也是缘分 LBA34 - Primary results from the phase 3 LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲ trial LBA36 - Final Analysis of RATIONALE-301: Randomized, Phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma Mini Oral session 1: Gynaecological cancersDate Sat, 10.09.2022 Time 08:30 - 10:00 LBA32 - Efficacy and safety of GX-188E, a therapeutic DNA vaccine, combined with pembrolizumab in HPV 16- and/or 18- positive advanced cervical cancer (Phase II): Safe and effective in both PD-L1 positive and negative Proffered Paper session 1: GU tumours, non-prostateDate Sat, 10.09.2022 Time 10:15 - 11:45 LBA66 - IMmotion010: efficacy and safety from the Phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection LBA67 - Phase III RandOmized Study Comparing PErioperative Nivolumab (nivo) versus Observation in Patients (Pts) with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC) Proffered Paper session: Breast cancer, early stageDate Sat, 10.09.2022 Time 10:15 - 11:45 LBA13 - Nivolumab and ipilimumab in early stage triple negative breast cancer (TNBC) with tumor-infiltrating lymphocytes (TILs): first results from the BELLINI trial LBA14 - Impact of age, Recurrence Score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Analysis of ADAPT and ADAPTcycle trials Mini Oral session: Head & neck cancerDate Sat, 10.09.2022 Time 10:15 - 11:45 LBA33 - 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase 2 study Mini Oral session: Breast cancer, metastaticDate Sat, 10.09.2022 Time 14:45 - 16:15 LBA18 - Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial LBA19 - Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): a randomized phase 3 trial LBA20 - Open-label, randomized study of lasofoxifene (LAS) vs fulvestrant (Fulv) for women with locally advanced/metastatic ER+/HER2- breast cancer (mBC), an estrogen receptor 1 (ESR1) mutation, and disease progression on aromatase (AI) and cyclin-dependent kinase 4/6 (CDK4/6i) inhibitors Proffered Paper session 1: Melanoma and other skin tumoursDate Sat, 10.09.2022 Time 14:45 - 16:15 LBA39 - Final 5-year results of the phase 2, multicenter, randomized, open-label trial of talimogene laherparepvec (T-VEC) neoadjuvant treatment (Tx) plus surgery vs immediate surgery in patients (pts) with resectable stage IIIB-IVM1a melanoma (MEL) LBA40 - Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma Proffered Paper session: Haematological malignanciesDate Sat, 10.09.2022 Time 14:45 - 16:15 Mini Oral session: GI, upper digestiveDate Sat, 10.09.2022 Time 14:45 - 16:15 LBA61 - HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: a multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC)Mini Oral session: Supportive and palliative careDate Sat, 10.09.2022 Time 16:30 - 18:00 LBA70 - COVID-19 in cancer patients: Update from the joint analysis of ESMO-CoCARE, BSMO, PSMO international databases Proffered Paper session: GU tumours, prostateDate Sun, 11.09.2022 Time 08:30 - 10:00 LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): overall survival (OS) results of 2 randomised Phase III trials from the STAMPEDE protocol LBA63 - PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer (AFT-19) Proffered Paper session: Non-metastatic NSCLC and other thoracic malignanciesDate Sun, 11.09.2022 Time 08:30 - 10:00 LBA47 - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC): updated results from ADAURA LBA48 - Community-based Mass Screening with Low-Dose CT for Lung Cancer in Guangzhou Proffered Paper session 1: GI, lower digestiveDate Sun, 11.09.2022 Time 10:15 - 11:45 LBA21 - FOLFOX/FOLFIRI plus either bevacizumab or panitumumab in patients with initially unresectable colorectal liver metastases (CRLM) and left-sided and RAS/BRAFV600E wild-type tumour: phase III CAIRO5 study of the Dutch Colorectal Cancer Group LBA22 - Phase III study with FOLFIRI/Cetuximab versus FOLFIRI/Cetuximab followed by Cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: the ERMES Study (NCT02484833) LBA23 - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): the SAMCO-PRODIGE 54 randomised phase II trial Mini Oral session: NSCLC, metastaticDate Sun, 11.09.2022 Time 10:15 - 11:45 LBA55 - Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutant Metastatic Non–Small Cell Lung Cancer (NSCLC): Interim Results From the Phase 2 DESTINY-Lung02 Trial PD-1 x CTLA-4，是骡子是马，不过骡子好还是马好 LBA56 - MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): a Phase 1b/2 trial LBA57 - Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): an open label, multi-center, randomized, phase 2 study LBA58 - Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small-cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: second interim analysis of phase 3 ORIENT-31 study LBA59 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y) Mini Oral session: GU tumours, prostateDate Sun, 11.09.2022 Time 10:15 - 11:45 LBA64 - Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial Proffered Paper session: NSCLC, metastaticDate Sun, 11.09.2022 Time 14:45 - 16:15 LBA51 - Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial LBA52 - Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study LBA53 - ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib LBA54 - Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non small cell lung cancer (NSCLC): the EMPOWER-Lung 1 trial Proffered Paper session 2: GI, upper digestiveDate Sun, 11.09.2022 Time 14:45 - 16:15 LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial LBA12 - Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with a FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial Mini Oral session: Basic science & translational researchDate Sun, 11.09.2022 Time 14:45 - 16:15 LBA72 - Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial Mini Oral session 1: GU tumours, non-prostateDate Sun, 11.09.2022 Time 14:45 - 16:15 LBA75 - RACE IT - A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18) – first results Mini Oral session: Melanoma and other skin tumoursDate Mon, 12.09.2022 Time 08:30 - 09:45 LBA41 - Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation LBA42 - Combined Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy for Advanced Merkel Cell Carcinoma LBA43 - Intradermal IMO-2125 versus placebo as adjuvant treatment in patients with stage II pT3-4/cN0 melanoma: interim efficacy and safety results of the randomized phase II INTRIM study LBA44 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial Mini Oral session: NETs and endocrine tumoursDate Mon, 12.09.2022 Time 08:30 - 10:00 LBA46 - Bevacizumab (B) plus FOLFIRI after failure of platinum-etoposide in patients (pts) with advanced neuroendocrine carcinoma (NEC): the PRODIGE 41-BEVANEC randomized phase II study Proffered Paper session 2: GI, lower digestiveDate Mon, 12.09.2022 Time 10:15 - 11:45 LBA24 - KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation LBA25 - FRESCO-2: A global phase 3 multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer Proffered Paper session 2: GU tumours, non-prostateDate Mon, 12.09.2022 Time 14:45 - 16:15 LBA68 - Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of Sunitinib or Cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a Phase 3 randomized study (PIVOT-09) LBA73 - Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) Mini Oral session: GI, lower digestiveDate Mon, 12.09.2022 Time 14:45 - 15:55 LBA26 - BREAKWATER safety lead-in (SLI): encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) LBA27 - Additional analyses of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC LBA28 - Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial Mini Oral session: Non-metastatic NSCLC and other thoracic malignanciesDate Mon, 12.09.2022 Time 14:45 - 16:15 LBA71 - First–line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743 LBA50 - Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816 Proffered Paper session: NETs and endocrine tumoursDate Mon, 12.09.2022 Time 16:30 - 18:00 LBA45 - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: the SEQTOR study (GETNE 1206) Mini Oral session 2: GU tumours, non-prostateDate Mon, 12.09.2022 Time 16:30 - 17:30 LBA69 - Belzutifan, a HIF-2α Inhibitor, for von Hippel-Lindau (VHL) Disease–Associated Neoplasms: 36 Months of Follow-Up of the Phase 2 LITESPARK-004 Study |
|
|
